ICEECE2012 Poster Presentations Endocrine tumours and neoplasia (112 abstracts)
Medical and Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Well and Moderately Differentiated Neuroendocrine Tumours
A. Bianchi , D. Iacovazzo , F. Lugli , A. Fusco , S. Chiloiro , M. Mormando , L. Tartaglione , G. Grande , A. Larghi , G. Schinzari , G. Doglietto , S. Margaritora , G. Perotti , G. Rindi , A. Pontecorvi & L. De Marinis
Policlinico “A. Gemelli” - Catholic University, Rome, Italy.
Introduction: Peptide receptor radionuclide therapy (PRRT) is a treatment choice for inoperable or metastasized neuroendocrine tumours and this therapy seems more effective in the biochemical and volume control of disease than somatostatin analogues (SSA).
Aims: To demonstrate the efficacy of medical therapy with SSA and PRRT in patients with well and moderately differentiated neuroendocrine tumours.
Materials and methods: We evaluated 60 patients (29 males, 31 females; mean age at diagnosis 53±17 years) affected by well and moderately differentiated neuroendocrine tumours. 26 patients (43%) were affected by bronchial carcinoids, 16 patients (27%) by intestinal neuroendocrine tumours, 15 patients (25%) by pancreatic neuroendocrine tumours, 3 patients (5%) by metastases from neuroendocrine carcinoma of unknown origin. 25 patients (42%) with either metastatic or recurrent disease, unresectable primary tumours or symptoms of hormone excess were treated with SSA. Among these, 10 patients (17%) with metastatic disease or unresectable primary tumours with intense hyperuptake at the Octreoscan underwent 2 to 7 cycles of PRRT with 90Y-DOTATOC or 177Lu-DOTATATE. Mean follow up was 41±10 months.
Results: Medical treatment with SSA allowed control of symptoms related to hormone excess in all patients but 1 with refractory carcinoid syndrome. Among the patients that underwent PRRT, 6 (60%) had minor or partial response, 3 (30%) had stable disease while 1 patient had progression of disease. Interestingly, 3 of the 6 patients with minor or partial response to PRRT had further progression with a mean PFS of 12.7 months.
Conclusions: Medical treatment with SSA allowed control of hormone secretion in the majority of patients. PRRT allowed minor or partial response of disease in a high proportion of treated patients. However, among these, a relatively high proportion of patients had further progression of disease.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more